Post‐hoc safety/efficacy analyses from pediatric delgocitinib atopic dermatitis trials
2024

Delgocitinib Ointment for Atopic Dermatitis in Children

Sample size: 240 publication 10 minutes Evidence: moderate

Author Information

Author(s): Tatsuki Fukuie, Hiroyuki Toyama, Mai Tanaka, Katsuyo Ohashi-Doi, Kenji Kabashima

Primary Institution: National Center for Child Health and Development, TORII Pharmaceutical Co Ltd, Graduate School of Medicine Kyoto University

Hypothesis

Is delgocitinib ointment safe and effective for treating atopic dermatitis in children?

Conclusion

Delgocitinib 0.5% ointment may be more effective than the 0.25% dose for mild atopic dermatitis, and it is well tolerated when used with other medications.

Supporting Evidence

  • 46.2% of children with mild disease using 0.25% ointment achieved clear or almost clear skin.
  • 71.4% of children with mild disease using 0.5% ointment achieved clear or almost clear skin.
  • No significant differences in safety profiles between the two ointment doses.

Takeaway

This study looked at a cream called delgocitinib to help kids with skin problems. It found that a stronger version of the cream works better for mild cases and is safe to use with other treatments.

Methodology

Post-hoc analysis of data from two double-blind placebo-controlled trials comparing 0.25% and 0.5% delgocitinib ointment in pediatric patients.

Limitations

The study is based on post-hoc analyses of short-term treatment data from a relatively small number of patients.

Participant Demographics

Pediatric patients aged 2-15 years with atopic dermatitis.

Digital Object Identifier (DOI)

10.1111/ped.15798

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication